COVALAB

In the biotechnology industry where the creation of any start-up depends on the input of the investors and on the fluctuations of the stock market, Covalab stands out as an exception. Indeed, with a minimum of initial capital and the assistance of University Claude Bernard (Lyon), the company developed slowly using as its foundation its know-how in Immunochemistry. The principal aim of its founding members (Dr. Saïd El Alaoui & Dr. Vincent Thomas) was to achieve national and international credibility. This is an original concept, a slow but worthwhile process, on the condition that it evolves according to the needs of the industry and remains firmly rooted in practical achievements. Covalab principal activity, which has allowed it to attain complete financial independence, is that devoted to the development of monoclonal & polyclonal antibodies destined for research, diagnosis and therapeutics. Some of the antibodies developed for pharmaceutical companies are among products having a strong potential for clinical application. Covalab also has its own wide range of products for research and diagnosis in areas as varied as cancer, neuroscience, auto-immune diseases, to mention only a few.

Contact Details: 11 avenue Albert Einstein Villeurbanne 69100 France Tel: +33(0) 437 654 230 Fax: +33(0) 437 289 416 Email: enquiries@covalab.com WWW: www.covalab.com

Recent Publications by COVALAB:
A review of in vitro modelling approaches to the identification and modulation of squamous metaplasia in the human tracheobronchial epithelium. Squamous metaplasia in the tracheobronchial epithelium (TBE) involves the...	8th February, 2008	Centre for Research in Biomedicine, University of the West of England,	Altern Lab Anim. 2007 Oct;35(5):493-504.
A role for tissue transglutaminase in alpha-gliadin peptide cytotoxicity. In coeliac disease, gliadin peptides p56-88, p57-68 and p31-49 have been...	21st February, 2007	Covalab, Villeurbanne, France.	Clin Exp Immunol. 2006 Dec;146(3):550-8. DOI Direct Link
Development of an immunocapture method for measuring IgA antibodies to tissue transglutaminase in the sera of patients with coeliac disease. One of the most reliable sero-diagnostic tests for coeliac disease (CD) is...	29th June, 2006		Clin Exp Immunol. 2006 Apr;144(1):101-9. DOI Direct Link
Development and evaluation of a modified colorimetric solid-phase microassay for measuring the activity of cellular and plasma (Factor XIII) transglutaminases. Plasma TG (transglutaminase) [FXIII (Factor XIII)] stabilizes fibrin and...	19th April, 2006	Covalab, 3, allee Pierre de Coubertin, 69007 Lyon, France.	Biotechnol Appl Biochem. 2006 Mar;43(Pt 3):171-9. DOI Direct Link
Definition of the fine specificity of the monoclonal antibody 81D4: its reactivity with lysine and polyamine isopeptide cross-links. The 81D1C2 monoclonal antibody (Mab) directed against the...	20th October, 2004	Covalab, 3, allee Pierre de Coubertin, 69007 Lyon, France.	J Immunol Methods. 2004 Sep;292(1-2):83-95. DOI Direct Link
→View more COVALAB research publications.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 120 times since April 2007, the link to the organisation's website has been followed 41 times

Recent Search Terms used to find this page: covalab france | covalab france | covalab fr | covalab | mAb 81D4 CovalAb Lyon France | CovalAb lyon France | covalab | CovalAb France | f | covalab dr said alaoui | .

Search for more companies in Villeurbanne

Search for more companies in

This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for COVALAB